On November 18, Intellia Therapeutics rose 5.32% in Regular Trading, trading at $10.35/share, with turnover of $5.52 million.
The move coincided with investor focus on the completion of enrollment in the MAGNITUDE-2 Phase 3 trial for nex-z in ATTRv-PN, alongside a recently reiterated Buy rating and $49 price target from Canaccord Genuity.
Earlier this month, the company said MAGNITUDE-2 enrollment was complete and reported cash of $614.8 million, which it expects will fund operations at least into 2028. That update helped offset a weaker third-quarter report released on November 5, when Intellia Therapeutics posted EPS of $(0.91) on revenue of $7.163 million, both below consensus expectations. More broadly, recent updates on lonvo-z, including positive Phase 3 hereditary angioedema data and regulatory progress, have reinforced the view that the company is moving closer to potential commercialization.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments